SARC002: Phase III Randomized Trial of 120-minute infusion Gemcitabine v. 90-minute infusion Gemcitabine plus Docetaxal in unresectable Soft Tissue Sarcoma: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society
PI: Robert Maki, MD PhD
Date Initiated: 1/2/2003
Date Terminated: 4/17/2007